Eli Lilly and Co

Recent news

• Rating change
  Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT) and Jade Biosciences (JBIO)
  TipRanks · 2026/10/1
• Company notice
  MMAG: Notice of Interest Sub. S-hldr (Section 137 of CA 2016) - MR CHEAH MIN LLY
  Bursa Malaysia · 2026/1/9
• Rating change
  J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,500
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• Rating change
  Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,371
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Rating change
  Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,330
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Form 144 | Eli Lilly and Co(LLY.US) Insider Proposes to Sell 347.25 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• Rating change
  Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,440
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Rating change
  BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• Rating change
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)
  TipRanks · 2026/10/1
• Rating change
  Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,440
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• Rating change
  Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,430
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Company notice
  MMAG: Notice of Interest Sub. S-hldr (Section 137 of CA 2016) - MR CHEAH MIN LLY (Amended Announcement)
  Bursa Malaysia · 2026/1/12
• Rating change
  RBC Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• Rating change
  Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• Rating change
  Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Rating change
  TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,250
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,430
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,341
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• Rating change
  DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,550
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• Rating change
  RBC Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• Rating change
  Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,600
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• Rating change
  Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/17

Headlines are aggregated automatically and are not independently verified or edited by our team.